Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,529.50
Bid: 1,531.50
Ask: 1,532.00
Change: 3.50 (0.23%)
Spread: 0.50 (0.033%)
Open: 1,537.00
High: 1,541.50
Low: 1,523.00
Prev. Close: 1,526.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

12 Dec 2018 16:35

RNS Number : 3061K
GlaxoSmithKline PLC
12 December 2018
 

GlaxoSmithKline plc (the 'Company')

Transaction notification

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.9439

8 (partnership shares)

£14.9439

8 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£14.9439

 

 

e)

Date of the transaction

2018-12-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R G Connor

b)

Position/status

President, Global Vaccines

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.9439

8 (partnership shares)

£14.9439

8 (matching shares)

 

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£14.9439

 

 

e)

Date of the transaction

2018-12-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr S Dingemans

b)

Position/status

Chief Financial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.9439

8 (partnership shares)

£14.9439

8 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£14.9439

 

 

e)

Date of the transaction

2018-12-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

  

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr N Hirons

b)

Position/status

SVP, Global Ethics & Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.9439

8 (partnership shares)

£14.9439

8 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£14.9439

 

 

e)

Date of the transaction

2018-12-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr L Miels

b)

Position/status

President, Global Pharmaceuticals

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.9439

8 (partnership shares)

£14.9439

8 (matching shares)

 

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£14.9439

 

 

e)

Date of the transaction

2018-12-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

  

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D S Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.9439

8 (partnership shares)

£14.9439

8 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£14.9439

 

 

e)

Date of the transaction

2018-12-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R Simard

b)

Position/status

President, Pharma Supply Chain

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.9439

9 (partnership shares)

£14.9439

9 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

18 Ordinary Shares

£14.9439

 

 

e)

Date of the transaction

2018-12-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms C Thomas

b)

Position/status

SVP, Human Resources

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.9439

8 (partnership shares)

£14.9439

8 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£14.9439

 

 

e)

Date of the transaction

2018-12-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P C Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.9439

8 (partnership shares)

£14.9439

8 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£14.9439

 

 

e)

Date of the transaction

2018-12-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mrs V A Whyte

b)

Position/status

Company Secretary

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.9439

8 (partnership shares)

£14.9439

8 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£14.9439

 

 

e)

Date of the transaction

2018-12-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHQLLFFVLFXFBZ
Date   Source Headline
7th Sep 20182:18 pmRNSDirector/PDMR Shareholding
3rd Sep 20185:00 pmRNSTotal Voting Rights
30th Aug 20185:12 pmRNSGSK publishes Q4 2018 Dividend Dates
30th Aug 20188:12 amRNSEU approve Nucala in severe asthma in children
24th Aug 201810:16 amRNSDirector/PDMR Shareholding
15th Aug 20187:00 amRNSPositive headline results for ViiV HC ATLAS study
10th Aug 20183:00 pmRNSDirector/PDMR Shareholding
8th Aug 201812:35 pmRNSDirector/PDMR Shareholding
7th Aug 20187:00 amRNSIain Mackay appointed GSK Chief Financial Officer
2nd Aug 20185:07 pmRNSPublication of Base Prospectus
2nd Aug 201811:04 amRNSTotal Voting Rights
31st Jul 20185:03 pmRNSDirector/PDMR Shareholding
31st Jul 20184:37 pmRNSDirector/PDMR Shareholding
27th Jul 20184:30 pmRNSDirector/PDMR Shareholding
27th Jul 20182:47 pmRNSCHMP recommend Nucala for severe asthma children
26th Jul 20187:00 amRNSGSK reports on FDA Ad Com on mepolizumab for COPD
25th Jul 20184:15 pmRNSDirector/PDMR Shareholding
25th Jul 201811:00 amRNSGSK and 23andMe Agreement
25th Jul 201811:00 amRNS2nd Quarter Results
24th Jul 20189:01 amRNSViiV announces Juluca 100 week data at AIDS 2018
24th Jul 20189:00 amRNSViiV shows positive phIII data on two-drug combo
19th Jul 20184:45 pmRNSDirector/PDMR Shareholding
17th Jul 20185:46 pmRNSDirector/PDMR Shareholding
17th Jul 20184:54 pmRNSDirector/PDMR Shareholding
17th Jul 20184:49 pmRNSDirector/PDMR Shareholding
16th Jul 20182:51 pmRNSDirector/PDMR Shareholding
16th Jul 201811:11 amRNSDirector/PDMR Shareholding
13th Jul 20184:16 pmRNSDirector/PDMR Shareholding
13th Jul 20184:16 pmRNSDirector/PDMR Shareholding
11th Jul 20182:42 pmRNSDirector/PDMR Shareholding
2nd Jul 20182:30 pmRNSTotal Voting Rights
14th Jun 20187:00 amRNSPositive headline results for ViiV GEMINI studies
12th Jun 20185:15 pmRNSDirector/PDMR Shareholding
12th Jun 20182:00 pmRNSGSK announces changes to Corporate Executive Team
1st Jun 20181:00 pmRNSGSK completes Consumer Healthcare buyout
1st Jun 20189:42 amRNSTotal Voting Rights
29th May 20187:00 amRNSGSK Once-daily single inhaler triple therapy COPD
21st May 201811:02 amRNSViiV granted EU marketing authorisation for Juluca
15th May 20181:39 pmRNSDirector/PDMR Shareholding
11th May 20183:17 pmRNSDirector/PDMR Shareholding
10th May 20185:20 pmRNSBlock listing Interim Review
9th May 20185:05 pmRNSDirector/PDMR Shareholding - replacement
9th May 201812:00 pmRNSDirectorate Change
3rd May 20186:31 pmRNSResult of General Meeting
3rd May 20186:29 pmRNSResult of AGM
1st May 20182:45 pmRNSTotal Voting Rights
27th Apr 201812:43 pmRNSDirector/PDMR Shareholding
26th Apr 20183:30 pmRNSDirector/PDMR Shareholding
25th Apr 201812:07 pmRNSSecond Price Monitoring Extn
25th Apr 201812:02 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.